Call us 24/7

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Cancer clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

48 Clinical Trials

The TAPUR study is a clinical trial that aims to improve our understanding of how commercially available anti-cancer drugs perform on a broader range of cancers, by matching the drugs to tumors with specific genomic mutations that the drugs are designed to target.

This is a phase II, randomized, double-blind, placebo-controlled, multi-center, comparative global study to determine the efficacy and safety of durvalumab-olaparib combination therapy vs. durvalumab-placebo (durvalumab monotherapy) as a first-line treatment in patients ineligible for platinum-based chemotherapy with unresectable stage IV urothelial cancer.

The main purpose of this study is to evaluate the anti-tumor activity of NKTR-214 in combination with nivolumab by assessing the objective response rate in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD-L1 expression. The efficacy will be assessed within the experimental Arm A, while Arm B will serve as a reference arm.

This study is designed to determine the efficacy and safety of durvalumab in combination with paclitaxel and multiple, novel oncology therapies and durvalumab with paclitaxel alone for the treatment of first-line, metastatic triple-negative breast cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a randomized (1:1), double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab or placebo plus chemotherapy as first-line therapy for locally advanced, unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a Phase 3, randomized, open-label, multicenter, global study designed to compare the efficacy and safety of BGB-A317 versus sorafenib as a first-line systemic treatment in patients with unresectable hepatocellular carcinoma.

This will be a phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) electroporation (EP) plus IV pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma, who are progressing or have progressed on pembrolizumab or nivolumab.

The primary objectives will be to determine the efficacy of MT-3724 as monotherapy in subjects with relapsed or refractory DLBCL based on the overall response rate (ORR) by the revised Lugano Classification for lymphoma adjusted according to lymphoma response to immunomodulatory therapy criteria (LYRIC) hereinafter referred to as “revised Lugano Criteria” (Cheson et al, 2014, 2016).